The oncological survival and prognosis of individuals receiving PD-1 inhibitor with and without immunologic cutaneous adverse events

The treatment response to new immunotherapy in advanced melanoma patients remains varied between individuals. Immune related cutaneous side effects may have prognostic value.

Source: Journal of the American Academy of Dermatology - June 20, 2019 Category: Dermatology Authors: L. Chan, S.J.E. Hwang, M. Kyaw, K. Byth, Matteo S. Carlino, S. Chou, P. Fernandez-Penas Source Type: research